Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast CancerW. Fraser Symmans, Smita Asare, Molly Klein et al.|JAMA Oncology|2021Cited by 110
Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIALDouglas Yee, Si Fan, A. DeMichele et al.|Cancer Research|2018Cited by 16